(415) 353-9888 (appts)
(415) 353-7023 (fax)

Box 1705, UCSF; San Francisco, CA 94143-1705

additional websites:

UCSF Physician Referral Directory

Columbia University, New York, NY, B.A., 1983, Psychology
George Washington University School of Medicine, Washington, DC, M.D., 1987, Medicine

Papers

Resection and IORT followed by three dimensional conformal radiotherapy with or without adjuvant chemotherapy. Jablons D, Roach M 3rd, Jahan T, Cameron R. Frontiers of Radiation Therapy and Oncology 31: 140-5, 1997

A Phase I Pharmacokinetic Trial of Paclitaxel in Patients with Hepatic Dysfunction: CALGB 9264. Venook AP, Egorin M, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain M, Kearns C, Schilsky R. Journal of Clinical Oncology 16 (5): 1811-1819, 1998

Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anti-Copper, Antiangiogenic Agent: Phase I Study. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan TM, Sondak VK, Strawderman M, LeCarperntier G, Merajver SD. Clinical Cancer Research 6: 1-10, 200

Stage II (N1) Lung Cancer. Choy O, Jahan T, Roach M 3rd, You L, Jablons D. Chest Surgery Clinics of North America 11(1): 39-59, 2001

Radical Pleurectomy/Decortication and Intraoperative Radiotherapy Followed by Conformal Radiation with or without Chemotherapy for Malignant Pleural Mesothelioma. Lee TT, Everett DL, Hui-Kuo G, Jahan TM, Roach M, Speight JL, Cameron RB, Philips TL, Chan A, Jablons DM. Journal of Thoracic and Cardiovascular Surgery 124(6): 1183-89, 2002

Mechanisms of Potential Treatment Strategies for Metastatic Disease in Non Small Cell Lung Cancer. Maslyar D, Jahan TM, Jablons DM. Semin Thorac Cardiovasc Surg. 16(1):40-50, 2004

Unusual Thoracic Problems in Patients with Malignancies: CASE 3. Carcinoid Tumor of the Thymus. Hansen EK, Krieg RM, Azar RJ, Jablons DM, Jahan TM. Journal of Clinical Oncology 23(12): 2859-2861, 2005

Receptor are Associated with Gefitinib Response in Chemo refractory Lung Adenocarcinomas. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Ronco MS, Hsue V, Jablons D, Sanchez JM, Moran T. Clinical Cancer Research 11(16):5878-85, 2005.

Phase 1/2 Trial of Autologous Tumor mixed with an Allogeneic GVAX® Vaccine in Advanced Stage Non-Small Cell Lung Cancer. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Banik G, Hege K. Cancer Gene Ther. 2006 Jun; 13(6):555-62

Small cell lung cancer clinical practice guidelines in oncology. Johnson BE, Crawford J, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F, Williams CC Jr; National Comprehensive Cancer Network (NCCN). J Natl Compr Canc Netw. 2006 4(6): 602-22

Non-small cell lung cancer clinical practice guidelines in oncology. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE; National Comprehensive Cancer Network (NCCN). J Natl Compr Canc Netw. 2006 Jul; 4(6):548-82.

Selected Abstracts:

Value of Imaging with Anti-TAG-72 Monoclonal Antibody (Oncoscint®) in the Management of Colorectal Carcinoma patients. Jahan TM, Venook AP, Price D, Frye JW, Warren RS, ASCO, 1994.

Paclitaxel (Taxol®) In Patients with Liver Dysfunction (CALGB 9264). Venook AP, Egorin M, Brown TD, Batist G, Budman DR, Rosner GL, Jahan TM, Schilsky RL, ASCO, 1994.

Plasma Pharmacokinetics and Biliary Excretion of Paclitaxel (Taxol®) in Patients with Hepatic Dysfunction. Egorin M, Venook AP, Jahan TM, Zuhowski M, Brown T, Vinciguerra V, Batist G, Rosner G, Schilsky R. 8th NCI-EORTC symposium on new drugs in cancer therapy, 1994.

Pegylated Liposome Encapsulated Doxorubicin (Doxil®) In Patients with Hepatocellular Carcinoma. Venook, AP, Amantea M, Bonnem E, McWatters C, Jahan TM, ASCO, 1996

The Use of IORT as a Component of Tri Modality Therapy for the Treatment of Mesothelioma. Shu HK, Jablons DM, Phillips TL, Vigneault E, Cameron RB, Jahan TM, Roach M. International Society of IORT, 1998

The Use of Radical Pleurectomy and IORT Followed by Conformal 3D External Beam Radiation Therapy with or without Chemotherapy in the Treatment of Malignant Pleural Mesothelioma. Shu HK, Jablons DM, Phillips TL, Vigneault E, Cameron RB, Jahan TM, Roach M. ASTRO, 1998

A Feasibility Study of Neoadjuvant Vinorelbine and Cis-platinum for Patients with Resectable Non Small Cell Lung Cancer. Jahan TM, Clary-Macy C, David G, McMillan A, Adams L, Jablons DM. ASCO, 1999.

A Phase II Study of T138067-Sodium in Prior Taxane-Treated Patients (Pts) with Locally Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC). Sandler A, Burris H, Krozely P, Jones S, Everett D, Giordano H, Stagg R, Jahan T. ASCO 2002

Epidermal Growth Factor Receptor (EGFR) activating mutations (muts) in the Tyrosine Kinase (TK) Domain Correlate with Gefitinib Response in Chemorefractory non-small cell lung cancer (NSCLC). Taron M, Ichinose Y, Rosell R, Masuti B, Manegold C, Queralt C, Jahan T, Hsue V, Jablons D. ASCO 2005

Neoadjuvant Chemotherapy with Gemcitabine-containing Regimens in Stage I-II Non-small Cell Lung Cancer (NSCLC): Initial Results of the GINEST†¦ Project (†¦Gemcitabine in Neoadjuvant Early Stage Trials). Detterbeck FC, Socinski MA , Gralla RJ, Edelman MJ, Jahan TM, Loesch D, Limentani SA, Govindan R, Bloss LP, Obasaju CK. ASCO 2005

Neoadjuvant Chemotherapy with Gemcitabine-containing Regimens in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC): Initial Results of pre-operative function testing (PFT's) in the GINEST†¦ Project (†¦Gemcitabine in Neoadjuvant Early Stage Trials). Rivera MP, Detterbeck FC, Socinski MA , Moore D, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Obasaju CK, Gralla RJ. ASCO 2005

The Impact of Neoadjuvant Chemotherapy and Surgery on Quality of Life (QL) in Patients with Early Stage NSCLC: A Prospective Analysis of the GINEST Project. Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch D, Limentani SA, Govindan R, Obasaju CK, Socinski MA. ASCO 2005

Vatalanib in patients with previously untreated and unresected advanced malignant mesothelioma (MM): Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Jahan TM, Gu L, Wang X, Kratzke RA, Green MR, Vokes EE, Kindler HL. (IASLC World Conference on Lung Cancer 2005)

Evaluating the Impact of Neoadjuvant Chemotherapy and Surgery on Quality of Life (QL) in Patients with Early Stage NSCLC: A Prospective Analysis of the GINEST Project. Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch D, Limentani SA, Govindan R, Obasaju CK, Bloss LP , Socinski MA. (IASLC World Conference on Lung Cancer 2005)

Activating mutations (muts) in the tyrosine Kinase domain of the epidermal growth factor receptor (EGFR) and of the platelet derived growth factor receptor a (PDGFRa) in gefitinib treated non small cell lung cancer (NSCLC) patients. Taron M, Santarpia C, Ichinose Y, Mok T, Massuti B, Queralt C, Sanchez J, Jahan T, Jablons D, Rosell R. (IASLC World Conference on Lung Cancer 2005)

Vatalanib (V) in malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). Jahan TM, Gu L, Wang X, Kratzke RA, Dudek AZ, Green MR, Vokes EE, Kindler HL, for the Cancer and Leukemia Group B. ASCO 2006

9/19/06